BRPI0518568A2 - mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico - Google Patents

mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico

Info

Publication number
BRPI0518568A2
BRPI0518568A2 BRPI0518568-8A BRPI0518568A BRPI0518568A2 BR PI0518568 A2 BRPI0518568 A2 BR PI0518568A2 BR PI0518568 A BRPI0518568 A BR PI0518568A BR PI0518568 A2 BRPI0518568 A2 BR PI0518568A2
Authority
BR
Brazil
Prior art keywords
influenza virus
composition
cell
replicative
nucleic acid
Prior art date
Application number
BRPI0518568-8A
Other languages
English (en)
Inventor
Emmie De Wit
Monique I J Spronken
Ron A M Fouchier
Albert D M E Osterhaus
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of BRPI0518568A2 publication Critical patent/BRPI0518568A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18611Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18651Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MÉTODO PARA PRODUZIR UMA PARTÍCULA DO VÍRUS DA INFLUENZA REPLICATIVO SEM O USO DE VÍRUS AUXILIAR, PARTÍCULA DE VÍRUS DA INFLUENZA REPLICATIVO, CÉLULA, COMPOSIÇçO, USO DE UMA COMPOSIÇçO, MÉTODO PARA GERAR PROTEÇçO IMUNOLàGICA CONTRA INFECÇçO DE UM INDIVÍDUO COM UM VÍRUS DA INFLUENZA, E, ÁCIDO NUCLÉICO. A invenção diz respeito ao campo da produção de vacinas da influenza. As vacinas da influenza têm sido produzidas em ovos de galinhas embrionados por mais de 50 anos, mas recentemente têm sido feitos consideráveis esforços para se desenvolver sistemas de cultura celular para a produção de vacina. A invenção proporciona um ácido nucleico compreendendo um segmento de gene da influenza e um promotor bacteriófago da polimerase ou um filamento complementar do referido ácido nucleico, e uma célula compreendendo um tal ácido nucleico capaz de produzir o desejado virus da influenza. Além do mais, a invenção provê uma composição compreendendo uma célula ou material derivado de uma célula de acordo com a invenção, e um vírus ou material derivado de uma partícula viral, de acordo com a invenção.
BRPI0518568-8A 2004-12-24 2005-12-22 mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico BRPI0518568A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078527 2004-12-24
US64100305P 2005-01-04 2005-01-04
PCT/EP2005/057092 WO2006067211A1 (en) 2004-12-24 2005-12-22 Rescue of influenza virus

Publications (1)

Publication Number Publication Date
BRPI0518568A2 true BRPI0518568A2 (pt) 2008-11-25

Family

ID=34928779

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518568-8A BRPI0518568A2 (pt) 2004-12-24 2005-12-22 mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico

Country Status (20)

Country Link
US (2) US7959930B2 (pt)
EP (2) EP2295542B1 (pt)
JP (2) JP5620048B2 (pt)
KR (1) KR101272487B1 (pt)
CN (1) CN101379183B (pt)
AU (1) AU2005318087B2 (pt)
BR (1) BRPI0518568A2 (pt)
CA (1) CA2592439C (pt)
DK (1) DK1831357T3 (pt)
ES (1) ES2395813T3 (pt)
HK (1) HK1125674A1 (pt)
IL (1) IL183888A (pt)
MX (1) MX2007007889A (pt)
NO (1) NO20073737L (pt)
NZ (1) NZ556061A (pt)
PT (1) PT1831357E (pt)
RU (2) RU2435855C2 (pt)
TW (2) TWI402344B (pt)
WO (1) WO2006067211A1 (pt)
ZA (1) ZA200705145B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1351981T3 (da) 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
US20040005545A1 (en) 2002-02-21 2004-01-08 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
CN101379183B (zh) * 2004-12-24 2013-07-03 雅培生物学有限责任公司 流感病毒的拯救
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
CA2613283A1 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing a heterologous protease
PT1951299E (pt) 2005-11-04 2012-02-28 Novartis Vaccines & Diagnostic Vacinas contra a gripe que incluem combinações de adjuvantes particulados e imuno-potenciadores
JP2009514850A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
DK2368572T3 (da) 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
US20090220541A1 (en) 2005-11-04 2009-09-03 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
EP2478916B1 (en) 2006-01-27 2020-04-01 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
US9254318B2 (en) 2006-03-31 2016-02-09 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
AU2007297178B2 (en) 2006-09-11 2014-07-24 Novartis Ag Making influenza virus vaccines without using eggs
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
NZ582595A (en) 2007-06-27 2012-07-27 Novartis Ag Low-additive influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
CA2752039A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
EP2396031A1 (en) 2009-02-10 2011-12-21 Novartis AG Influenza vaccines with increased amounts of h3 antigen
FR2949344A1 (fr) 2009-04-27 2011-03-04 Novartis Ag Vaccins de protection contre la grippe
WO2011012999A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
EP2576773A2 (en) * 2010-06-02 2013-04-10 Avir Green Hills Biotechnology Research Development Trade AG Methods and helper viruses for the generation of rna virus
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
AU2012324398A1 (en) 2011-10-20 2014-05-01 Seqirus UK Limited Adjuvanted influenza B virus vaccines for pediatric priming
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
US10080794B2 (en) 2013-03-15 2018-09-25 University Of Maryland, College Park Swine influenza viruses and constructs and uses thereof
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
CA2986701A1 (en) 2015-06-09 2016-12-15 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
AU2016290603B2 (en) 2015-07-07 2022-06-02 Seqirus UK Limited Influenza potency assays
EP3417056A1 (en) 2016-02-19 2018-12-26 Wisconsin Alumni Research Foundation (WARF) Improved influenza b virus replication for vaccine development
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
JP2022551805A (ja) 2019-08-27 2022-12-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたhaを持つ組換えインフルエンザウイルス

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) * 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
BRPI0009580B8 (pt) 1999-04-06 2021-05-25 Wisconsin Alumni Res Found processo para preparar vírus influenza infecciosos na ausência de um vírus auxiliar, preparação de vírus influenza infeccioso recombinante, e, composição.
DK1194580T4 (da) 1999-07-14 2011-01-03 Sinai School Medicine In-vitro rekonstitution af segmenterede negativstrengede RNA-virus
AU6514900A (en) * 1999-08-02 2001-02-19 Wyeth Rescue of mumps virus from cdna
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
ATE420189T1 (de) 2000-04-28 2009-01-15 St Jude Childrens Res Hospital Dna-transfektionssystem zur erzeugung von infektiösen negativsträngigen rna virus
BR0111819A (pt) * 2000-06-23 2004-01-06 American Cyanamid Co Moléculas de ácido nucléico isoladas, e, seq ência de aminoácido isolada
US20040005545A1 (en) * 2002-02-21 2004-01-08 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
EP1499348B1 (en) * 2002-04-26 2014-10-01 MedImmune, LLC Method for producing infectious influenza b virus in cell culture
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
CN101379183B (zh) * 2004-12-24 2013-07-03 雅培生物学有限责任公司 流感病毒的拯救

Also Published As

Publication number Publication date
AU2005318087A1 (en) 2006-06-29
RU2435855C2 (ru) 2011-12-10
HK1125674A1 (en) 2009-08-14
JP5702321B2 (ja) 2015-04-15
JP2012147789A (ja) 2012-08-09
AU2005318087B2 (en) 2011-04-21
TWI402344B (zh) 2013-07-21
RU2007128336A (ru) 2009-01-27
KR101272487B1 (ko) 2013-06-07
NZ556061A (en) 2009-06-26
JP2008525003A (ja) 2008-07-17
ES2395813T3 (es) 2013-02-15
JP5620048B2 (ja) 2014-11-05
PT1831357E (pt) 2012-12-17
EP1831357B1 (en) 2012-10-17
TW201235472A (en) 2012-09-01
IL183888A0 (en) 2007-10-31
US20120156241A1 (en) 2012-06-21
NO20073737L (no) 2007-09-21
IL183888A (en) 2013-05-30
EP1831357A1 (en) 2007-09-12
RU2011122117A (ru) 2012-12-10
WO2006067211A1 (en) 2006-06-29
US7959930B2 (en) 2011-06-14
ZA200705145B (en) 2009-09-30
CN101379183A (zh) 2009-03-04
EP2295542A1 (en) 2011-03-16
CA2592439A1 (en) 2006-06-29
KR20070110838A (ko) 2007-11-20
TWI495724B (zh) 2015-08-11
DK1831357T3 (da) 2012-12-10
EP2295542B1 (en) 2013-01-30
CA2592439C (en) 2014-06-03
TW200636070A (en) 2006-10-16
CN101379183B (zh) 2013-07-03
MX2007007889A (es) 2008-01-22
US20080050401A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
BRPI0518568A2 (pt) mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico
Chen et al. Advances in development and application of influenza vaccines
EP2465919B1 (en) Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines
EP2010557B1 (en) High titer recombinant influenza viruses for vaccines
WO2021155243A8 (en) Respiratory virus immunizing compositions
Devarajan et al. New insights into the generation of CD4 memory may shape future vaccine strategies for influenza
DE60139026D1 (de) Lebender influenza impfstoff und verfahren zu seiner herstellung
HRP20120790T1 (hr) Cjepiva protiv influence sa niskom koliäśinom aditiva
EP1697521A4 (en) PLASMID MULTIPLE SYSTEM FOR PRODUCING INFLUENZA VIRUS
AR082427A2 (es) Sistemas de expresion de virus parainfluenza recombinantes y vacunas que comprenden antigenos heterologos derivados de metapneumovirus
WO2016061232A3 (en) Multiplexed shrnas and uses thereof
EA200900784A1 (ru) Вакцины, включающие антиген из четырех штаммов вируса гриппа
GB2503066A8 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
AU2014202470A1 (en) High titer recombinant influenza viruses for vaccines
MX2018006373A (es) Produccion de virus en cultivos celulares.
WO2005090584A2 (de) Impfstoff gegen influenza basierend auf geflügelpestviren
WO2004034956A2 (de) 8-plasmid methode mit mutiertem ha gen zur herstellung eines influenza-impfstoffes
AU2011253998A1 (en) Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines
Fischer et al. A51 NEW INSIGHTS INTO PATHOGENS AND HOST DEFENSE: Live Attenuated Influenza Vaccines Elicit A Greater Innate Immune Response Than Antigenically Matched Seasonal Influenza Viruses During Infection Of Human Nasal Epithelial Cells
KR20180084336A (ko) 마우스에 대한 병원성이 증가된 인플루엔자 a 바이러스
WO2016148195A9 (ja) インフルエンザウイルス作出用細胞
MY179706A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
UA112748C2 (uk) Комбінована фармацевтична композиція та метод лікування та запобігання інфекційним хворобам

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ERASMOS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) ,

Free format text: TRANSFERIDO DE: SOLVAY PHARMACEUTICALS B.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ERASMOS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) ,

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]